The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss
Open accessAbstract
Type I protein arginine methyltransferases (PRMTs) catalyze asymmetric dimethylation of arginines on proteins. Type I PRMTs and their substrates have been implicated in human cancers, suggesting inhibition of type I PRMTs may offer a therapeutic approach for oncology. The current report describes GSK3368715 (EPZ019997), a potent, reversible type I PRMT inhibitor with anti-tumor effects in human cancer models. Inhibition of PRMT5, the predominant type II PRMT, produces synergistic cancer cell growth inhibition when combined with GSK3368715. Interestingly, deletion of the methylthioadenosine phosphorylase gene (MTAP) results in accumulation of the metabolite 2-methylthioadenosine, an endogenous inhibitor of PRMT5, and correlates with sensitivity to GSK3368715 in cell lines. These data provide rationale to explore MTAP status as a biomarker strategy for patient selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
RSeQC: quality control of RNA-seq experiments
Wang, L., Wang, S., & Li, W. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts356 · Cited by 2,788
Shen, S., Park, J. W., Lu, Z.-X., Lin, L., Henry, M. D., Wu, Y. N., Zhou, Q., & Xing, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419161111 · Cited by 2,713
Protein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,792
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Self-citationHulsen, T., de Vlieg, J., & Alkema, W. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-488 · Cited by 1,674
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Protein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607
Self-citationA selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569
Self-citationThe PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 513
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Immunoaffinity Enrichment and Mass Spectrometry Analysis of Protein Methylation
Guo, A., Gu, H., Zhou, J., Mulhern, D., Wang, Y., Lee, K. A., Yang, V., Aguiar, M., Kornhauser, J., Jia, X., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o113.027870 · Cited by 474
Pawlak, M. R., Scherer, C. A., Chen, J., Roshon, M. J., & Ruley, H. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.13.4859-4869.2000 · Cited by 355
Yoshimatsu, M., Toyokawa, G., Hayami, S., Unoki, M., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Maehara, Y., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25366 · Cited by 313
Protein arginine-methyltransferase-dependent oncogenesis
Cheung, N., Chan, L. C., Thompson, A., Cleary, M. L., & So, C. W. E. (2007) · Nature Cell Biology · doi:10.1038/ncb1642 · Cited by 291
CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis
Wang, L., Zhao, Z., Meyer, M. B., Saha, S., Yu, M., Guo, A., Wisinski, K. B., Huang, W., Cai, W., Pike, J. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.007 · Cited by 264
Measure transcript integrity using RNA-seq data
Wang, L., Nie, J., Sicotte, H., Li, Y., Eckel-Passow, J. E., Dasari, S., Vedell, P. T., Barman, P., Wang, L., Weinshiboum, R., et al. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0922-z · Cited by 254
Sam68 RNA Binding Protein Is an In Vivo Substrate for Protein Arginine N -Methyltransferase 1
Côté, J., Boisvert, F.-M., Boulanger, M.-C., Bedford, M. T., & Richard, S. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-08-0484 · Cited by 250
Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs
Dhar, S., Vemulapalli, V., Patananan, A. N., Huang, G. L., Di Lorenzo, A., Richard, S., Comb, M. J., Guo, A., Clarke, S. G., & Bedford, M. T. (2013) · Scientific Reports · doi:10.1038/srep01311 · Cited by 228
Gerhart, S. V., Kellner, W. A., Thompson, C., Pappalardi, M. B., Zhang, X.-P., Montes de Oca, R., Penebre, E., Duncan, K., Boriack-Sjodin, A., Le, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28002-y · Cited by 206
Self-citationProtein arginine methylation of non-histone proteins and its role in diseases
Wei, H., Mundade, R., Lange, K., & Lu, T. (2014) · Cell Cycle · doi:10.4161/cc.27353 · Cited by 190
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity
Zhao, X., Jankovic, V., Gural, A., Huang, G., Pardanani, A., Menendez, S., Zhang, J., Dunne, R., Xiao, A., Erdjument-Bromage, H., et al. (2008) · Genes & Development · doi:10.1101/gad.1632608 · Cited by 186
Takai, H., Masuda, K., Sato, T., Sakaguchi, Y., Suzuki, T., Suzuki, T., Koyama‐Nasu, R., Nasu‐Nishimura, Y., Katou, Y., Ogawa, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.071 · Cited by 171
Papasaikas, P., Tejedor, J. R., Vigevani, L., & Valcárcel, J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.10.030 · Cited by 164
Ren, J., Wang, Y., Liang, Y., Zhang, Y., Bao, S., & Xu, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103911 · Cited by 152
Arginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1
Zheng, S., Moehlenbrink, J., Lu, Y.-C., Zalmas, L., Sagum, C. A., Carr, S. M., McGouran, J. F., Alexander, L. T., Fedorov, O., Munro, S., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.039 · Cited by 149
The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation
Nicholson, T. B., Chen, T., & Richard, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.07.006 · Cited by 146
Localization of Methylated Arginine in the A1 Protein from Myelin
Brostoff, S. W., & EYLAR, E. H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.765 · Cited by 140
Stokes, M. P., Farnsworth, C. L., Moritz, A., Silva, J. C., Jia, X., Lee, K. A., Guo, A., Polakiewicz, R. D., & Comb, M. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015883 · Cited by 128
Shia, W.-J., Okumura, A. J., Yan, M., Sarkeshik, A., Lo, M., Matsuura, S., Komeno, Y., Zhao, X., Nimer, S. D., Yates, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-04-347476 · Cited by 124
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
Shailesh, H., Zakaria, Z. Z., Baiocchi, R. A., & Sif, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26404 · Cited by 119
Wang, Y., Xiao, X. G., Zhang, J., Choudhury, R., Robertson, A. D., Li, K., Ma, M., Burge, C. B., & Wang, Z. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2459 · Cited by 112
McGrath, J. P., Williamson, K. E., Balasubramanian, S., Odate, S., Arora, S., Hatton, C., Edwards, T. M., O’Brien, T., Magnuson, S. R., Stokoe, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2333 · Cited by 111
Discovery of a Dual PRMT5–PRMT7 Inhibitor
Smil, D. V., Eram, M. S., Li, F., Kennedy, S., Szewczyk, M. M., Brown, P. J., Baršytė-Lovejoy, D., Arrowsmith, C. H., Vedadi, M., & Schapira, M. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500467h · Cited by 99
Veland, N., Hardikar, S., Zhong, Y., Gayatri, S., Dan, J., Strahl, B. D., Rothbart, S. B., Bedford, M. T., & Chen, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.082 · Cited by 90
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis
Greenblatt, S. M., Man, N., Hamard, P.-J., Asai, T., Karl, D. L., Martínez, C., Bilbao, D., Stathias, V., Jermakowicz, A. M., Duffort, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.007 · Cited by 85
Self-citationCARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features
Akoum, R. E., Gauchotte, G., Oussalah, A., Wissler, M.-P., Clément-Duchêne, C., Vignaud, J.-M., Guéant, J., & Namour, F. (2013) · Biochimie · doi:10.1016/j.biochi.2013.10.021 · Cited by 78
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer
Almeida-Rios, D., Graça, I. C. R., Vieira, F. Q., Ramalho-Carvalho, J., Pereira-Silva, E., Martins, A. T., Oliveira, J., Gonçalves, C. S., Costa, B. M., Henrique, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10061 · Cited by 61
Arginine methyltransferases in normal and malignant hematopoiesis
Greenblatt, S. M., Liu, F., & Nimer, S. D. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.03.009 · Cited by 60
Gurunathan, G., Yu, Z., Coulombe, Y., Masson, J., & Richard, S. (2015) · Scientific Reports · doi:10.1038/srep10475 · Cited by 52
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer
Hsu, J. H.-R., Hubbell-Engler, B., Adelmant, G., Huang, J., Joyce, C. E., Vázquez, F., Weir, B. A., Montgomery, P. G., Tsherniak, A., Giacomelli, A. O., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0216 · Cited by 42
Cited by
The regulation, functions and clinical relevance of arginine methylation
Guccione, E., & Richard, S. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0155-x · Cited by 625
Amino acid metabolism in health and disease
Ling, Z.-N., Jiang, Y.-F., Ru, J.-N., Lu, J.-H., Ding, B., & Wu, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01569-3 · Cited by 545
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Wu, Q., Schapira, M., Arrowsmith, C. H., & Barsyte-Lovejoy, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00159-8 · Cited by 419
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Lu, S. X., De Neef, E., Thomas, J. D., Sabio, E., Rousseau, B., Gigoux, M., Knorr, D. A., Greenbaum, B., Elhanati, Y., Hogg, S. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.038 · Cited by 284
Metadata
- Authors
- Fedoriw, A., Rajapurkar, S. R., O'Brien, S., Gerhart, S. V., Mitchell, L. H., Adams, N. D., Rioux, N., Lingaraj, T., Ribich, S. A., Pappalardi, M. B., Shah, N., Laraio, J., Liu, Y., Butticello, M., Carpenter, C. L., Creasy, C., Korenchuk, S., McCabe, M. T., McHugh, C. F., Nagarajan, R., Wagner, C., Zappacosta, F., Annan, R., Concha, N. O., Thomas, R. A., Hart, T. K., Smith, J. J., Copeland, R. A., Moyer, M. P., Campbell, J., Stickland, K., Mills, J., Jacques-O’Hagan, S., Allain, C., Johnston, D., Raimondi, A., Porter Scott, M., Waters, N., Swinger, K., Boriack-Sjodin, A., Riera, T., Shapiro, G., Chesworth, R., Prinjha, R. K., Kruger, R. G., Barbash, O., & Mohammad, H. P.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 36
- Issue
- 1
- Pages
- 100-114.e25
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2954328834
- Cited by
- 339
- References
- 48
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.